Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp Issues Q2 2013 Mixed Guidance; Lowers FY 2013 Revenue Guidance; Raises Low End Of Prior FY 2013 EPS Guidance


Thursday, 25 Apr 2013 07:03am EDT 

Boston Scientific Corp announced that it estimates sales in a range of $1.740-$1.800 billion, earnings on a GAAP basis in a range of $0.07 to $0.10 per share and adjusted earnings, excluding acquisition- and restructuring-related charges; and amortization expense, in a range of $0.14 to $0.17 per share for the second quarter of 2013. The Company estimates sales in a range of $6.950-$7.150 billion, (losses) earnings on a GAAP basis in a range of ($0.06) to $0.01 per share and adjusted earnings, excluding goodwill impairment charges, acquisition-, restructuring-, and litigation-related charges, divestiture-related net credits and amortization expense; are estimated in a range of $0.65 to $0.70 per share for fiscal 2013. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $1.812 billion and EPS of $0.10 for the second quarter of 2013; revenue of $7.183 billion and EPS of $0.41 for fiscal 2013. 

Company Quote

12.78
-0.36 -2.74%
4:02pm EDT